INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
Corporate insider
NS

Nagendran Sukumar

Director, President and Head of R&DCIK 0001665124

EDGAR filingsOpen in network
Disclosed transactions12
Buys / sells0 / 4
Max Insider Score32
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
11
NS
Nagendran SukumarDirector, President and Head of R&D
TSHATaysha Gene Therapies, Inc.
Open-market sale · 10b5-1 plan
SELL$892K
200.0K sh
Apr 10, 2026Apr 13, 2026
traded Apr 10, 2026
+3dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Taysha Gene Therapies, Inc.Director, President and Head of R&D · Jan 14, 2026
0
NS
Nagendran SukumarDirector, President and Head of R&D
TSHATaysha Gene Therapies, Inc.
Option exercise · 10b5-1 plan
M
—
19.0K sh
Apr 10, 2026
Apr 13, 2026
traded Apr 10, 2026
+3d
SEC FORM 4

Evidence

0
NS
Nagendran SukumarDirector, President and Head of R&D
TSHATaysha Gene Therapies, Inc.
Option exercise · 10b5-1 plan
M$33K
19.0K sh
Apr 10, 2026Apr 13, 2026
traded Apr 10, 2026
+3dSEC FORM 4

Evidence

32
NS
Nagendran SukumarDirector, President and Head of R&D
TSHATaysha Gene Therapies, Inc.
Open-market sale
SELL$423K
89.1K sh
Jan 23, 2026Jan 27, 2026
traded Jan 23, 2026
+4dSEC FORM 4

Evidence

25
NS
Nagendran SukumarDirector, President and Head of R&D
TSHATaysha Gene Therapies, Inc.
Open-market sale
SELL$124K
26.9K sh
Jan 26, 2026Jan 27, 2026
traded Jan 26, 2026
+1dSEC FORM 4

Evidence

11
NS
Nagendran SukumarDirector, President and Head of R&D
TSHATaysha Gene Therapies, Inc.
Option exercise · 10b5-1 plan
M—
111.3K sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

7
NS
Nagendran SukumarDirector, President and Head of R&D
TSHATaysha Gene Therapies, Inc.
Option exercise · 10b5-1 plan
M—
88.7K sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

0
NS
Nagendran SukumarDirector, President and Head of R&D
TSHATaysha Gene Therapies, Inc.
Grant or award · 10b5-1 plan
A—
274.0K sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

6
NS
Nagendran SukumarDirector, President and Head of R&D
TSHATaysha Gene Therapies, Inc.
Option exercise · 10b5-1 plan
M$78K
111.3K sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

6
NS
Nagendran SukumarDirector, President and Head of R&D
TSHATaysha Gene Therapies, Inc.
Option exercise · 10b5-1 plan
M$152K
88.7K sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

20
NS
Nagendran SukumarDirector, President and Head of R&D
TSHATaysha Gene Therapies, Inc.
Open-market sale · 10b5-1 plan
SELL$942K
200.0K sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

7
NS
Nagendran SukumarDirector, President and Head of R&D
TSHATaysha Gene Therapies, Inc.
Grant or award · 10b5-1 plan
A—
427.0K sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence